NuCana
NuCana [NCNA] is an oncology focused Biopharma company dedicated to the development and commercialization of new medicines to treat patients with cancer. The ProTide Technology Platform has the potential to transform chemotherapy to targeted therapy. ProTides have been designed to target specific patient populations for whom existing chemotherapy is not likely to be effective. By overcoming the key resistance pathways, ProTides aim to significantly improve the efficacy, broaden the clinical utility, and improve the safety profile of many established anticancer agents.
Sector
Biopharmaceuticals
Strategies
Capital
Status
Active
Website
www.nucana.com
SofinnovaCapital
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
SofinnovaMD Start
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
SofinnovaDigital Medicine
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.